Avenue therapeutics reports third quarter 2023 financial results and recent corporate highlights

- phase 1b/2a clinical trial of aj201 remains on track to report topline data in second quarter of 2024 - - positive baer-101 preclinical data accepted for presentation at american epilepsy society (aes) annual meeting - - agreement reached with u.s. fda on study design and analysis approach for phase 3 safety study of iv tramadol - - raised $5 million in gross proceeds from public equity offering - miami, nov. 13, 2023 (globe newswire) -- avenue therapeutics, inc. (nasdaq: atxi) (“avenue” or the “company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the third quarter ended september 30, 2023. “in the third quarter, avenue continued to successfully execute across our pipeline of innovative cns treatments," said alexandra maclean, m.d.
ATXI Ratings Summary
ATXI Quant Ranking